Company news
Vertex Pharmaceuticals Incorporated news in 2025
Vertex Pharmaceuticals Incorporated's news releases, calls and decks from 2025, newest first.
Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
February 9, 2025
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
January 30, 2025
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
January 29, 2025
Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
January 26, 2025
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
January 9, 2025
Calls in 2025
- Vertex Pharmaceuticals (NASDAQ:VRTX) Q3 2025 Earnings Call
Nov 3, 2025
Transcript - Vertex Pharmaceuticals (NASDAQ:VRTX) Q2 2025 Earnings Call
Aug 4, 2025
Transcript - Vertex Pharmaceuticals (NASDAQ:VRTX) Q1 2025 Earnings Call
May 5, 2025
Transcript - Vertex Pharmaceuticals (NASDAQ:VRTX) Q4 2024 Earnings Call
Feb 10, 2025
Transcript
Decks in 2025
- American Society of Nephrology Kidney Week 2025
Conference · 42 slides · Nov 8, 2025
- Q3 2025 Earnings Presentation
Earnings · 20 slides · Nov 3, 2025
- Q1 2025 Earnings Presentation
Earnings · 20 slides · May 5, 2025
- Q4 2024 Earnings Presentation
Earnings · 19 slides · Feb 10, 2025